Active, not recruitingPhase 2NCT03962543
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Studying Neurofibroma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SpringWorks Therapeutics, Inc.
- Principal Investigator
- Christopher L Moertel, MDUniversity of Minnesota
- Intervention
- Mirdametinib (PD-0325901) oral capsule or dispersible tablet(drug)
- Enrollment
- 114 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2019 – 2023
Study locations (20)
- University of Alabama at Birmingham/Children's of Alabama, Birmingham, Alabama, United States
- Mayo Clinic Hospital, Phoenix, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- UCLA Oncology Center, Los Angeles, California, United States
- University of California - Irvine Health, Orange, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
- University of California - Davis Comprehensive Cancer Center, Sacramento, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Nemours A. I. duPont Hospital for Children, Wilmington, Delaware, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Florida Clinical Research Center, Gainesville, Florida, United States
- Nicklaus Children's Hospital, Miami, Florida, United States
- AdventHealth Pediatric Oncology Hematology at Orlando, Orlando, Florida, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03962543 on ClinicalTrials.govOther trials for Neurofibroma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT06175637Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNsAstraZeneca
- ACTIVE NOT RECRUITINGNANCT05891847Non-interventional Study of Patients With PN NF1 Starting Selumetinib in RussiaAstraZeneca
- RECRUITINGNANCT05199376Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1Centre Leon Berard
- RECRUITINGPHASE1NCT02390752Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...National Cancer Institute (NCI)